PTC Therapeutics (PTCT) Bullish Stance Reiterated at Cowen on Strong Translarna Sales Growth

Go back to PTC Therapeutics (PTCT) Bullish Stance Reiterated at Cowen on Strong Translarna Sales Growth

PTC Therapeutics (PTCT) Misses Q3 EPS by 12c

November 9, 2015 4:49 PM EST

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.27), $0.12 worse than the analyst estimate of ($1.15). Revenue for the quarter came in at $9.78 million versus the consensus estimate of $9.88 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

... More